argenx | News

The Latest

News

May 26, 2020

argenx Announces Positive Topline Phase 3 ADAPT Trial Results

Breda, the Netherlands / Ghent, Belgium

argenx today announced positive topline data from the pivotal ADAPT trial of efgartigimod. ADAPT met its primary endpoint defined as percentage of responders on the Myasthenia Gravis Activities of Daily Living (MG-ADL) score among acetylcholine receptor-antibody positive (AChR-Ab+) generalized myasthenia gravis (gMG) patients.

argenx Announces Positive Topline Phase 3 ADAPT Trial Results

argenx Announces Positive Topline Phase 3 ADAPT Trial Results

More Press Releases

News

June 3, 2020

argenx to Present at Goldman Sachs 41st Annual Global Healthcare Conference

argenx today announced that Tim Van Hauwermeiren, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020 at 8:00 a.m. ET.

News

June 1, 2020

argenx announces closing of global offering

argenx announced today the closing of its previously announced global offering of an aggregate of 4,207,292 ordinary shares (including ordinary shares represented by American Depositary Shares (ADSs)), which includes the full exercise of the underwriters’ option to purchase 548,777 additional ADSs.

News

May 29, 2020

argenx announces full exercise of underwriters’ option to purchase additional ADSs

argenx announced today that the underwriters of its previously announced global offering of ordinary shares have exercised their option to purchase 548,777 additional ADSs in full on the same terms and conditions as the global offering.

Media Center

May 1, 2020

Making Asthma Crystal Clear

April 16, 2020

Monoclonal antibodies against GARP/TGF-b1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo

April 13, 2020

ARGX-116 / A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels

April 8, 2020

Protein crystallization promotes type 2 immunity and is reversible by antibody treatment

April 7, 2020

SIMPLE Antibody platform / Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy